Cellceutix Reports Positive Interim Results from Brilacidin Phase 2 Clinical Trial

Cellceutix Reports Positive Interim Results from Brilacidin Phase 2 Clinical Trial
Positive interim results were reported in the first two groups of ulcerative colitis patients being treated with Brilacidin (PMX-30063) in a dose-escalating Phase 2 clinical trial. Patients for a third and final group — testing the highest dose — are now being recruited. The open-label and proof-of-concept study is testing the treatment's safety and effectiveness at three dose levels —  50 mg, 100 mg, and 200 mg — in a total of 18 people with ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS), both limited forms of ulcerative colitis. Its primary goal is disease remission, and patients are being given Brilacidin by retention enema daily at bedtime for 42 days, the treatment's developer, Cellceutix Corporation, announced in a  press release. All 12 patients in groups A and B have completed treatment with Brilacidin, and all showed a good response to the treatment as assessed by the Modified Mayo Disease Activity Index (MMDAI), the company reported. Those patients' evaluations, reviewed by a trial safety committee, were a requirement for enrolling a third and final group. Cellceutix also reported that the study met its primary efficacy endpoint in six patients (three in each group), meaning that at day 42, these people were
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *